ScoreComparison
Why is Rigel Pharmaceuticals, Inc. ?
1
Flat results in Mar 26
- NET SALES(Q) At USD 58.82 MM has Fallen at -20.05%
- PRE-TAX PROFIT(Q) At USD 11.66 MM has Fallen at -61.73%
- OPERATING PROFIT(Q) Lowest at USD 12.48 MM
2
With ROE of 93.75%, it has a attractive valuation with a 1.22 Price to Book Value
- Over the past year, while the stock has generated a return of 69.99%, its profits have risen by 1998.5%
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Consistent Returns over the last 3 years
- Along with generating 69.99% returns in the last 1 year, the stock has outperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Rigel Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Rigel Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Rigel Pharmaceuticals, Inc.
69.99%
3.15
70.76%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
22.06%
EBIT Growth (5y)
44.64%
EBIT to Interest (avg)
-5.21
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
2.98
Tax Ratio
2.48%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
526.12%
ROE (avg)
40.05%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
1
Industry P/E
Price to Book Value
1.22
EV to EBIT
2.99
EV to EBITDA
2.93
EV to Capital Employed
1.29
EV to Sales
1.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
43.35%
ROE (Latest)
93.75%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 79.27 MM
NET PROFIT(HY)
Higher at USD 276.72 MM
RAW MATERIAL COST(Y)
Fallen by -0.48% (YoY
CASH AND EQV(HY)
Highest at USD 301.64 MM
-15What is not working for the Company
NET SALES(Q)
At USD 58.82 MM has Fallen at -20.05%
PRE-TAX PROFIT(Q)
At USD 11.66 MM has Fallen at -61.73%
OPERATING PROFIT(Q)
Lowest at USD 12.48 MM
OPERATING PROFIT MARGIN(Q)
Lowest at 21.22 %
NET PROFIT(Q)
Lowest at USD 8.65 MM
EPS(Q)
Lowest at USD 0.44
Here's what is working for Rigel Pharmaceuticals, Inc.
Operating Cash Flow
Highest at USD 79.27 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Cash and Eqv
Highest at USD 301.64 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by -0.48% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Rigel Pharmaceuticals, Inc.
Net Sales
At USD 58.82 MM has Fallen at -20.05%
over average net sales of the previous four periods of USD 73.57 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Pre-Tax Profit
At USD 11.66 MM has Fallen at -61.73%
over average net sales of the previous four periods of USD 30.46 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD 8.65 MM has Fallen at -90.57%
over average net sales of the previous four periods of USD 91.76 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Operating Profit
Lowest at USD 12.48 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Operating Profit Margin
Lowest at 21.22 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Net Profit
Lowest at USD 8.65 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
EPS
Lowest at USD 0.44
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
